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Background: Adults living in the sunny Australian climate are at high risk of skin cancer, but vitamin D deficiency
(defined here as a serum 25-hydroxyvitamin D (25(OH)D) concentration of less than 50 nmol/L) is also common.
Vitamin D deficiency may be a risk factor for a range of diseases. However, the optimal strategies to achieve and
maintain vitamin D adequacy (sun exposure, vitamin D supplementation or both), and whether sun exposure itself
has benefits over and above initiating synthesis of vitamin D, remain unclear.
The Sun Exposure and Vitamin D Supplementation (SEDS) Study aims to compare the effectiveness of sun exposure
and vitamin D supplementation for the management of vitamin D insufficiency, and to test whether these
management strategies differentially affect markers of immune and cardio-metabolic function.
Methods/Design: The SEDS Study is a multi-centre, randomised controlled trial of two different daily doses of
vitamin D supplementation, and placebo, in conjunction with guidance on two different patterns of sun exposure.
Participants recruited from across Australia are aged 18–64 years and have a recent vitamin D test result showing a
serum 25(OH)D level of 40–60 nmol/L.
Discussion: This paper discusses the rationale behind the study design, and considers the challenges but necessity
of data collection within a non-institutionalised adult population, in order to address the study aims. We also discuss
the challenges of participant recruitment and retention, ongoing engagement of referring medical practitioners and
address issues of compliance and participant retention.
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The incidence of skin cancer is high and rising in most
developed countries where the population is predomin-
antly fair-skinned [1]. Indeed, skin cancer is the most
common cancer in many of these countries [2,3], a con-
sequence of inappropriately high levels of exposure to
ultraviolet (UV) radiation. Sun exposure also has bene-
fits for health such as the initiation of cutaneous vitamin
D synthesis. Yet even in locations with high skin cancer
incidence, vitamin D deficiency (defined here as a serum
25-hydroxyvitamin D (25(OH)D) concentration of less
than 50 nmol/L) is not uncommon [4]. Sun protection
programs, developed following recognition of strato-
spheric ozone depletion and burgeoning skin cancer in-
cidence, are now being challenged to find a balance that
minimizes risk of skin cancer but allows sufficient sun
exposure to maintain adequate vitamin D status [5]. Re-
cent surveys show that health professionals and the pub-
lic are confused and concerned about the amount of sun
exposure that is optimal for health [6,7]. One option is
to encourage sun avoidance and increase vitamin D in-
take from food or supplements. However, recent studies
suggest that there may be beneficial effects of sun expos-
ure through non-vitamin D pathways [8-11]. An alterna-
tive strategy is thus to encourage sufficient sun exposure
to ensure adequate vitamin D status and provide these
potential non-vitamin D-related benefits.
In Australia, current sun exposure guidelines recom-
mend the use of sun protection when the UV Index is 3
or greater. Sun protection includes seeking shade when
outdoors, covering up with clothing, using sunscreen on
exposed skin, and wearing sunglasses and a hat [12].
Australia has the highest skin cancer incidence in the
world: 2 in every 3 Australians will develop a non-
melanoma skin cancer by the age of 70 years [3] while
the incidence of melanoma of the skin is four-fold higher
than the average for more developed regions of the
world [13]. Nevertheless, in the most recent Australian
Health Survey, 23% of the Australian population aged
12 years and over were vitamin D deficient (25(OH)D
concentration of <50 nmol/L), with higher prevalence of
deficiency during winter and at higher latitude locations
[4]. It is not clear whether current sun protection guide-
lines are compatible with achieving and maintaining vita-
min D adequacy. It is also unclear whether modified sun
exposure advice can be safely used to optimise vitamin D
status, as an alternative to vitamin D supplementation.
There is considerable indirect evidence that suggests
vitamin D has beneficial effects on health, including for
several internal cancers, cardiovascular disease, fracture
prevention and mental health. Many studies have used
latitude, ambient ultraviolet (UV) radiation levels, or his-
tory of personal sun exposure as a presumed proxy for
vitamin D status (for example, [14]). Other studies havedirectly measured the serum concentration of 25(OH)D
to assess vitamin D status. Many experimental studies
show that there are plausible biological pathways, and
associations between disease and genes of the vitamin D
pathway further implicate vitamin D as important in dis-
ease etiology or outcome [15]. However, although low 25
(OH)D levels are associated with a range of chronic
diseases, vitamin D supplementation trials and meta-
analyses of trial data have not generally found a benefi-
cial effect on the health outcomes tested [16].
Sun exposure and, to a lesser degree, latitude and am-
bient levels of UV radiation, are proxies of vitamin D
status. Equally, lower vitamin D status is a marker of a
range of other potential disease risk factors, such as low
levels of physical activity, or low sun exposure itself.
Clinical trials of vitamin D supplementation may be null
because the vitamin D doses used are too low, the sup-
plementation duration is for too short a time period, or
compliance with the intervention is poor [17]. Alterna-
tively, the results of observational studies may be incor-
rect because of reverse causation or failure to adequately
control for confounding – or because the 25(OH)D level
is simply a proxy for sun exposure, time outdoors or as-
sociated behaviours. Experimental studies show that sun
exposure has positive effects on immune function and
cardio-metabolic health, working through both vitamin
D and non-vitamin D pathways [8,18,19]. Any positive
non-vitamin D pathway effects of sun exposure will not
be apparent in vitamin D supplementation trials and
may explain the discrepancies between observational
studies and clinical trials.
Understanding whether there are separate beneficial ef-
fects of sun exposure and vitamin D for health is import-
ant for framing public health messages: if non-vitamin D
pathways are important, then some sun exposure may be
required; if not, then sun avoidance and vitamin D supple-
mentation would achieve vitamin D sufficiency and min-
imise the risk of UV-induced skin cancer.
The Sun Exposure and Vitamin D Supplementation
Study (SEDS Study) was developed to rigorously assess
the independent effects of sun exposure and vitamin D
supplementation on: i) the management of mild vitamin
D deficiency; and ii) relevant markers of immune function
and cardio-metabolic health. In this paper we describe the
methods of the SEDS Study, including the challenges
posed by nationwide participant recruitment, measure-
ment of sun exposure and vitamin D status, provision of
vitamin D supplementation and placebo, and maintenance
of participant engagement and compliance over a 12-
month period.
Methods/Design
The study design is summarised in Figure 1. Eligible par-
ticipants are assigned to one of four study regions,
Routine blood test 
25 (OH)D=40-60 nmol/L
General practitioner or self-
referral
Assessment of eligibility criteria
Completion of baseline materials
Placebo D
Enhanced sun 
exposure advice
Placebo D
Standard sun 
exposure advice
600 IU D
Standard sun 
exposure advice
2000 IU D
Standard sun 
exposure advice
Medicare Australia
Questionnaires
UV radiation exposure: diary, dosimeter 1 week every 3 months
Blood sampling: baseline, summer, winter, 12 months
Figure 1 Study design for the Sun Exposure and Vitamin D Supplementation Study.
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east (New South Wales and Australian Capital Territory),
north (Queensland), and south (Victoria, Tasmania, South
Australia). Within each study region, participants are ran-
domly allocated to one of four study arms (using random
number sequences), for a 12-month intervention of:
1. Vitamin D3 2000 IU/day taken orally as a softgel
capsule with meals and provision of advice to follow
Australian Cancer Council guidelines for sun
exposure, which recommend using sun protection if
the UV Index is 3 or more. This is the “standard”
sun exposure advice (SSEA), and will be a
continuation of usual practice for many people.
2. Vitamin D3 600 IU/day taken orally as a softgel
capsule with meals and provision of SSEA.
3. Placebo softgel capsule (containing gelatin) and
provision of SSEA.
4. Placebo softgel capsule and provision of “enhanced”
sun exposure advice (ESEA) guidelines. ESEA
guidelines advise the participant to have several brief
(10–15 minute) periods of sun exposure each day,
protecting the head and neck, but otherwise
exposing as much of the body surface as is
practicable, without sunscreen. If longer periods of
sun exposure are planned, participants are advised
to follow Cancer Council Australia guidelines for
sun protection. Participants in this arm are provided
with a sun exposure monitor that is calibrated for
their skin type and delivers an audible warning when
the total dose of UV radiation for a day nears one
minimum erythemal dose (MED, the dose of UVradiation that results in just perceptible reddening of
the skin).
At baseline and three-monthly, participants are asked
to complete questionnaires providing information about
demographic and personal characteristics, dietary intake,
medical history (including medications) and sun expos-
ure over the previous 3 months. At these time points,
participants are also asked to maintain a one-week sun
exposure, clothing, and physical activity diary and to
wear UV dosimeters to measure the received dose of UV
radiation. The UV dosimeter is worn at the wrist and is
either polysulphone, in which case two dosimeters are
supplied, one to be used on a usual working day and the
other on a usual non-working day, or an electronic
dosimeter to be worn each day for the diary week. Par-
ticipants have a blood sample taken at baseline, end of
study, end of summer and end of winter, with serum and
buffy coat (for DNA) aliquots stored at −80°C until ana-
lyses are carried out at the completion of the study.
The primary outcome of the SEDS Study is the change
in 25(OH)D levels over the 12 months of the trial across
the four study arms. Secondary outcomes are changes in
blood markers of immune function and cardio-metabolic
health across the four arms of the study and in relation to
measured sun exposure and 25(OH)D levels.
The SEDS Study is registered with the Australian Clinical
Trials Registry (ACTRN 12613000290796) and has been
approved by the Human Research Ethics Committees of
The Australian National University and The University of
Western Australia. Participants are required to provide
written informed consent prior to entry into the Study.
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safe and ethical conduct of a trial, adequate statistical
power, and applicability of the results to the broad range of
environmental conditions found across Australia.
Participant recruitment
Participants are primarily self-referred or recruited through
primary care physicians (general practitioners, GPs). In
addition, a random selection of adults with a vitamin D test
billed to the Australian medical insurance scheme, Medi-
care, are mailed an invitation to participate in the Study.
Once referred, potential participants are assessed for eligi-
bility (see below) against the inclusion and exclusion cri-
teria. If eligible and interested in participating, initial
questionnaires and a consent form are mailed out and, on
return of the completed material, participants are rando-
mised as described above.
Eligibility criteria
Eligible participants are aged 18–64 years with a recent
25(OH)D level of 40–60 nmol/L (previous month) and a
Fitzpatrick skin type of II-IV [20], determined by ques-
tions asked during an initial telephone assessment. Ex-
clusion criteria include current treatment for vitamin D
deficiency and medical conditions for which sun expos-
ure and/or vitamin D supplementation may be contrain-
dicated (see below).
Discussion: considerations informing the study
design
In the following sections, the ethical and statistical con-
cerns are discussed with respect to each of the important
aspects of the study design.
Ethical concerns
Exclusion of participants with skin type I (eligibility
criterion: skin type II to IV).
Fitzpatrick skin types are widely used in photobiology as
a measure of sun sensitivity. Skin type is assessed using
a brief questionnaire (for example [21]) and categorised
as I (very fair) to VI (very dark). There is considerable
variability in the minimum erythemal dose (MED, the
dose of UV radiation that causes a barely perceptible
reddening of the skin) within each skin type category
and overlap between the categories [22]. The enhanced
sun exposure advice given within the SEDS Study is for
a change in the pattern rather than the overall amount
of sun exposure. The sun exposure monitor provided to
participants in the ESEA arm is set to the individual’s
skin type. To allow for the variation in sensitivity to UV
radiation within each Fitzpatrick skin type, each monitor
is set conservatively to alarm well before the average
MED for that skin type. Participants are requested to re-
port any instance where they developed erythema afterbeing outdoors and the sun exposure monitor did not
alarm. In this situation, the participant would be
instructed to enter one skin type lower into the monitor.
Thus, skin type I is excluded from the study, to minimise
the risk that participants will be sunburnt while following
the ESEA guidelines.Exclusion of participants with a 25(OH)D level less than
40 nmol/L (eligibility criterion: recent vitamin D result of
40–60 nmol/L)
To the best of our current knowledge, there is no harm
in delaying treatment of people with a 25(OH)D level of
40–60 nmol/L for one year [23]. If there is a causal asso-
ciation between vitamin D deficiency and disease risks,
the increased risk appears to be primarily in those with
very low 25(OH)D levels (e.g. <30 nmol/L) [24]. Each
participant in the SEDS Study has a one in four chance
of being in the placebo vitamin D and SSEA group and
will not receive any active treatment. Hence we have
chosen a conservative cut-off of 40 nmol/L, below which
there is stronger evidence that active treatment for
vitamin D deficiency may be required.Exclusion of participants at high risk of skin cancer
Participants with low 25(OH)D levels are likely to have
had low recent sun exposure. If they follow the sun ex-
posure advice for their intervention arm, they may re-
ceive a higher dose of UV radiation than would have
otherwise occurred. Potential participants who report
that they are being monitored due to a high risk for skin
cancer, have had a previous diagnosis of melanoma or
squamous cell carcinoma, or more than five basal cell
carcinomas (BCCs) removed in the past five years, are
thus excluded from participation. BCC is extremely
common in adults in Australia [3] so that it is not prac-
ticable to exclude anyone who has had a single previous
BCC diagnosed. The ESEA includes advice to always
wear a hat and protect the face, neck and ears with sun-
screen when outdoors, as most skin cancers arise in
these areas [25].Exclusion of medical conditions where sun exposure or
vitamin D supplementation may have adverse effects
Although the doses of vitamin D supplementation used
in the SEDS Study are relatively low, potential partici-
pants with a history of the following medical conditions
are excluded from participation, since the intervention
could adversely affect their health (or that of their off-
spring): sarcoidosis, history of renal calculi, uncontrolled
endocrine disease, hepatic or renal disease, photosensi-
tivity diseases such as systemic lupus erythematosus with
cutaneous manifestations, pregnancy or lactation.
Hartley et al. BMC Public Health  (2015) 15:115 Page 5 of 9Doses of vitamin D supplementation
The United States Institute of Medicine (IOM) Recom-
mended Dietary Allowance of vitamin D for adults aged
up to 70 years with limited sun exposure is 600 IU/day
[26]. The current recommendation in Australia is 200–
400 IU/day (depending on age), with a maximum dose of
3200 IU/day [27]. In the SEDS Study, we have chosen to
use the dose recommended by the IOM (i.e., 600 IU/day)
as our lower reference point against which to assess the
effectiveness of sun exposure in raising 25(OH)D levels,
and an upper dose of 2000 IU/day as this has been previ-
ously shown to effectively raise 25(OH)D levels without
evidence of toxicity over a prolonged period of adminis-
tration [28].
Enhanced sun exposure advice (ESEA) as an intervention
Previous work has shown that the amount of the body
surface area that is exposed to the sun strongly influ-
ences vitamin D production [29,30]. Prolonged sun
exposure can result in degradation of vitamin D in the
skin to non-biologically active photo-products [31].
Thus, the ESEA focuses on short, frequent sun exposure,
with as much skin exposed as is feasible for the circum-
stances. If longer periods in the sun are planned, partici-
pants are advised to use sun protection if the UV Index
is 3 or more. The UV Index is available on daily weather
forecasts on television, radio, internet, in most daily
newspapers in Australia, and on the Cancer Council
Australia website. This information is provided to partic-
ipants in their sun exposure guidelines.
Enhancing the statistical power of the SEDS study
The study aims to recruit 228 participants in each group,
spread evenly across the four study regions (west, east,
north, and south, as described above). Assuming 20% at-
trition over the one year of the study, this sample size
will have 90% power to show equivalence in the post-
intervention mean serum levels of 25(OH)D, assuming
that equivalence is plus or minus 1/3 of the standard de-
viation (that is, ± 5 nmol/L) [32].
Exclusion of individuals under 18 or over 64 years old
(eligibility criterion: aged 18–64 years)
Restricting participation in the SEDS Study to a specific
age group limits the generalisability of the findings, and
thus requires careful consideration. Elderly people tend
to have lower vitamin D status than younger people,
possibly due to lower cutaneous stores of the precursor,
7-dehydrocholesterol [33]. In addition, skin cancer inci-
dence increases exponentially with increasing age [3].
We considered that the risks for skin cancer may out-
weigh the benefits of vitamin D synthesis, for the doses
of UV radiation required to achieve and maintain vita-
min D sufficiency in older adults. Although there is noclearly defined age cut-off, we excluded people over the
age of 64 years from participation in the SEDS Study.
Participation in the study is limited to adults due to the
greater difficulties involved in relation to consent, re-
cruitment and taking blood from children (<18 years).
Exclusion of individuals with 25(OH)D level over 60 nmol/L
(eligibility criterion: recent 25(OH)D result of between
40–60 nmol/L)
The change in 25(OH)D level following both exposure
to UV radiation and vitamin D supplementation depends
on the baseline 25(OH)D concentration [34,35]. Add-
itionally, the increase in 25(OH)D level is not linear, and
plateaus at approximately 70–80 nmol/L [36,37]. Partici-
pants with a recent 25(OH)D level of >60 nmol/L are
excluded from participation, so as to maximise the evi-
dence of the response to sun exposure or vitamin D
supplementation.
Exclusion of individuals with skin type V or VI (eligibility
criterion: skin type II–IV)
Although there is debate about whether more deeply
pigmented skin produces less vitamin D following UV ir-
radiation than paler skin, the weight of current evidence
suggests that this does occur and is particularly evident
for lower doses of UV radiation [34,38]. We have thus
chosen to exclude individuals with skin types V and VI
from the SEDS Study, although additional work is re-
quired to specifically study the needs of people with
these darker skin types.
Exclusion of individuals currently taking vitamin D
supplementation
The doses of vitamin D supplementation chosen are
relatively low compared to those used in other supple-
mentation trials. Individuals who are currently taking a
daily multivitamin (containing more than 200 IU vitamin
D3), are asked to switch to one containing no, or low
dose, vitamin D in order to be eligible to participate in
the Study. The aim is to avoid contamination across the
groups, maintaining minimal supplemental vitamin D in
the placebo arms and ensuring that the low-dose arm re-
mains as a low-dose, intermediate group.
Multicentre trial–participants recruited from across
Australia
The SEDS Study is recruiting Australia-wide in order to
provide wide variation in levels of ambient solar UV ra-
diation, as well as the amplitude of the seasonal variabil-
ity, and temperature, which affects patterns of clothing
and time outdoors. Australia spans a wide range of lati-
tudinal zones, from Darwin at 12° South to Hobart at
43° South. This results in considerable variation in the
typical sun exposure and doses of UV radiation. For
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winter), the maximum UV Index in Darwin in the
Northern Territory is around 8, compared to Kingston
(15 km from Hobart) in Tasmania, which has a max-
imum UV Index of around 1. The SEDS Study aims to
contribute to the evidence base for messages of optimal
sun exposure (amount and pattern) under different cli-
matic conditions, including temperature, humidity and
ambient UV radiation. Australia provides a good loca-
tion to assess this broad range of climatic conditions,
within a homogeneous healthcare system and a popula-
tion that is relatively homogeneous in terms of compos-
ition across different regions.
Challenges in study methodology
Recruitment methods
Recruiting nearly 1000 people across Australia with a re-
cently measured 25(OH)D level within a specific range
is challenging. Random selection from a population
register is not feasible, unless the study then carries out
screening for the 25(OH)D level. The main route of re-
cruitment is through GPs who identify potential partici-
pants following vitamin D testing undertaken as part of
routine clinical care. Research in general practice is
known to be difficult due to the time pressures faced in
this environment. We have therefore worked hard to ini-
tially elicit support and then to maintain engagement
using the following methods.
To recruit GPs to assist with the SEDS Study, we use
face-to-face meetings with GPs, their practice managers
and practice nurses, our personal networks, academic
units of general practice attached to universities and
medical schools, faxes to regional GP mailing lists, ad-
vertisements in GP newsletters, conference flyers, and
unannounced visits to general practices. The latter is the
least productive, and face-to-face contact the most
productive in terms of generating referral of potential
participants.
The GPs and their medical practices are provided with
information about the study aims, methods and how pa-
tients can be referred to the study. In some cases, and
only with the permission of the GP, pathology providers
have agreed to add a comment to the pathology report
for patients with a serum 25(OH)D of 40–60 nmol/L
stating that the patient may be eligible for the SEDS
Study. GPs receiving the 25(OH)D result seek the pa-
tient’s consent to release his/her contact details to the
SEDS Study team via fax, email or the SEDS website, in-
cluding confirmation that the patient has agreed to the re-
lease of his/her contact details. To maximise participant
recruitment and maintain GP interest and commitment to
the Study, researchers visit practices in person throughout
all study regions and provide regular study updates via
email or post, including relevant publications.Participants can also self-refer in response to media
coverage, the study website (http://www.sedsstudy.org/),
or the clinical trials register. However, many of these po-
tential participants are not eligible because they have ei-
ther not had a recent vitamin D test or are already being
treated for vitamin D deficiency. Vitamin D testing is
common in Australia, (there were 4 million tests in
2013–4) and has been subsidised by the government
medical insurance agency, Medicare. We have used a
mail out to a random sample of people who have re-
cently claimed the rebate for a vitamin D test, inviting
claimants to contact study personnel to discuss possible
participation. We are thus using a multi-pronged ap-
proach to maximise recruitment to the SEDS Study.
Enhancing accurate data collection
Where possible, the SEDS Study uses validated question-
naires for data collection that can be completed online
or in hard-copy. Tools to facilitate the accuracy and
standardisation of data collection include online videos
and a set of Frequently Asked Questions (FAQs). The
online videos describe how to take an accurate measure-
ment of waist circumference, how to use the two types
of dosimeter, and also how to complete one of the more
complex questionnaires. The FAQs provide guidance for
each of the more complicated questionnaires, and are
modified as new questions arise.
Enhancing compliance
Participant compliance is known to be a challenge in
clinical trials [39]. To optimise compliance we contact
participants weekly by SMS text message, email or tele-
phone, to remind them to take their study medication
and follow their sun exposure advice every day for the
entire year. Each week the SMS focuses on one of the el-
ements of the sun exposure guidelines specific to the
participant’s intervention group. For the participants in
the SSEA groups, these guidelines are the standard “Slip,
Slap, Slop, Seek and Slide” messages used by Cancer
Council Australia. Participants receiving the ESEA re-
ceive specially developed guidelines made to look and
sound familiar: Skin (expose as much skin as possible),
Short time (brief sun exposures), Slap (wear a hat), Slide
(wear sunglasses), Safe (use the sun exposure monitor)
and Stride (be physically active). In order to enhance
compliance with the sun exposure guidelines, partici-
pants are provided with a postcard-sized magnet for the
refrigerator that has the specific sun exposure guidelines
in a simple, colourful and easy-to-read image so that
participants will see the guidelines many times each day.
Participant retention over a 12-month period
Each participant is involved in the SEDS Study for one
year. In addition to the weekly reminders, study
Hartley et al. BMC Public Health  (2015) 15:115 Page 7 of 9personnel make regular contact by telephone or email.
Packages are posted to the participants every three
months for data collection, and blood collection forms
are sent four times a year; these provide additional op-
portunities to engage with participants. The SEDS Study
website has information about, and photographs of, the
study team – since the researchers do not meet the par-
ticipants, this is an opportunity to make the team as
“real” as possible. In addition, a study Facebook page al-
lows participants to communicate with the study team.
Participants who complete the entire 12 months of
participation are entered into a draw for one of several
shopping vouchers. Since the study will be ongoing over
nearly two years, a draw is held for every 200 partici-
pants completing the SEDS Study.
Study outcomes
Sun exposure for the management of mild vitamin D
insufficiency
Using this intervention study design, the SEDS Study
will test whether advice to change the pattern of sun ex-
posure can effectively achieve and maintain vitamin D
adequacy (serum 25(OH)D levels of 50 nmol/L or
higher) over 12 months. We will also calibrate the effect-
iveness of ESEA against different doses of vitamin D
supplementation. In secondary analyses we will examine
actual sun exposure over one year (from questionnaire,
diary and dosimeter data) in relation to vitamin D suffi-
ciency, and according to a range of parameters including
age, sex, body mass index and levels of physical activity.
These findings will have direct clinical applicability for
primary care physicians seeing community-dwelling pa-
tients with mild vitamin D insufficiency and needing to
choose management options.
Separate effects of sun exposure and vitamin D on immune
and cardio-metabolic function
At the completion of the SEDS Study we will measure,
on the stored blood, levels of specific immune and
cardio-metabolic markers for which there is past evi-
dence from experimental studies that a vitamin D or a
sun exposure effect is likely to be apparent. For immune
function, these markers include DNA methylation of the
FoxP3 gene as a measure of T regulatory cell number
and function [40,41]; total and house dust mite-specific
IgE levels [42-44]; varicella zoster IgG (King, unpub-
lished data). Previous work on sun exposure, vitamin D
and cardio-metabolic health suggests that the following
markers are likely to show an effect of changes in vitamin
D or exposure to the sun: fasting lipid profile [45-47]; fast-
ing serum glucose [48-50]; fasting serum leptin and adipo-
nectin [51-53]. The intervention study design has been
deliberately chosen to allow us to examine whether ESEA
(and higher sun exposure) and vitamin D supplementation(and measured 25(OH)D and vitamin D metabolites) have
independent effects on these markers of immune function
and cardio-metabolic health.
What is the potential value of the SEDS Study?
Research in Australia and New Zealand has shown that
both health professionals [7,54] and the public [6] are
confused about the health benefits and risks of vitamin
D supplementation and sun exposure. The SEDS Study
has been specifically designed to recruit a population
sample to provide an evidence base to clarify some of
the issues of concern.
Firstly the study aims to assess and quantify the effect of
advice to change the pattern of sun exposure in achieving
and maintaining vitamin D adequacy, compared to differ-
ent doses of vitamin D supplementation. This is an out-
come of direct value to clinicians managing vitamin D
deficiency.
Secondly, the study builds on recent evidence to sug-
gest that sun exposure and vitamin D may have inde-
pendent effects on disease risks [10,11,55,56]. In these
observational studies, although there is evidence of stat-
istical independence, vitamin D status and sun exposure
are closely inter-related, and measurement of both is
subject to considerable error. It is difficult therefore to
be confident of the existence or relative magnitude of
any independent effects. The intervention study design
is specifically being used in the SEDS Study to test these
factors and to unravel some of the confusion surround-
ing vitamin D and sun exposure.
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